ロード中...

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

OBJECTIVE: We reported previously that empagliflozin—a sodium-glucose cotransporter (SGLT) 2 inhibitor—exhibited preventive effects against obesity. However, it was difficult to extrapolate these results to human subjects. Here, we performed a therapeutic study, which is more relevant to clinical si...

詳細記述

保存先:
書誌詳細
出版年:BMJ Open Diabetes Res Care
主要な著者: Xu, Liang, Nagata, Naoto, Chen, Guanliang, Nagashimada, Mayumi, Zhuge, Fen, Ni, Yinhua, Sakai, Yuriko, Kaneko, Shuichi, Ota, Tsuguhito
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827766/
https://ncbi.nlm.nih.gov/pubmed/31749970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-000783
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!